Capstan Medical Receives Investment for Development of Heart Valve Devices

August 16, 2023—Capstan Medical, a developer of minimally invasive technology to address heart valve disease, recently announced an oversubscribed $31.4 million Series B investment.

According to the company, it is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform. In the coming months, the company will expand its engineering, clinical development, and operations teams to progress its technology through the next stage of development into first human use.

Capstan Medical, founded in 2020, is led by industry veterans Maggie Nixon, CEO, and co-founder Dan Wallace, CTO.

The investment was led by Eclipse, a United States venture capital firm with over $4 billion in assets under management and 70-plus portfolio companies. Other participating investors include Intuitive Ventures and Puma Venture Capital.

Capstan Medical advised that with the investment, Justin Butler, Partner at Eclipse, has been appointed to the company’s board.